Stocks and Investing
Stocks and Investing
Mon, January 23, 2023
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
Mani Foroohar Maintained (BBIO) at Buy with Decreased Target to $19 on, Jan 23rd, 2023
Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Decreased Target from $23 to $19 on, Jan 23rd, 2023.
Mani has made no other calls on BBIO in the last 4 months.
There is 1 other peer that has a rating on BBIO. Out of the 1 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mani
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $19 on, Friday, November 18th, 2022
Contributing Sources